千红制药(002550) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥352,007,088.55, a decrease of 13.97% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥126,792,812.09, an increase of 60.84% year-on-year[2] - The net profit excluding non-recurring gains and losses for Q3 2024 was ¥48,778,115.49, down 9.80% from the previous year[2] - The basic earnings per share for Q3 2024 was ¥0.1015, reflecting a 64.24% increase compared to the same period last year[2] - Total operating revenue for the period was CNY 1,207,602,942.05, a decrease of 17.6% compared to CNY 1,465,941,311.21 in the previous period[13] - Net profit for the period was CNY 298,597,921.90, an increase of 59.1% compared to CNY 187,652,324.30 in the previous period[14] - Earnings per share (EPS) for the period was CNY 0.2471, up from CNY 0.1549 in the previous period[15] - The company’s total comprehensive income for the period was CNY 298,737,624.85, compared to CNY 186,086,657.27 in the previous period[15] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,762,272,162.00, a slight decrease of 0.14% from the end of the previous year[2] - The total assets amounted to CNY 2,762,272,162.00 and equity amounted to CNY 2,484,899,948.42 respectively[12] - The total liabilities decreased from ¥292,172,947.64 to ¥277,372,213.58, a decline of approximately 5.1%[11] - The company’s total liabilities and equity decreased slightly from CNY 2,766,081,444.15 to CNY 2,762,272,162.00[12] Cash Flow - Operating cash inflow for the current period was CNY 1,303,233,031.89, a decrease of 32.8% from CNY 1,939,647,154.95 in the previous period[16] - Net cash flow from operating activities increased to CNY 450,750,025.74, up 15.2% from CNY 391,002,276.99 year-over-year[16] - Cash outflow from investing activities was CNY 303,959,223.80, a decrease of 8.0% compared to CNY 329,978,441.76 in the previous period[17] - Net cash flow from investing activities improved to -CNY 58,777,577.01, an improvement of 45.8% from -CNY 108,039,608.48 year-over-year[17] - Cash inflow from financing activities decreased significantly to CNY 3,000,000.00 from CNY 442,500,000.00 in the previous period[17] - Net cash flow from financing activities was -CNY 325,099,885.02, worsening from -CNY 226,310,659.25 year-over-year[17] - The ending balance of cash and cash equivalents increased to CNY 637,459,832.53, up from CNY 464,690,328.84 in the previous period[17] Expenses and Costs - The company's gross profit margin improved, contributing to a net profit increase due to the recovery of previously provisioned bad debts[5] - Research and development expenses increased compared to the previous year, impacting the net profit excluding non-recurring items[5] - The company's development expenditures increased to ¥99,660,827.47 from ¥70,162,324.03, representing a growth of about 42.3%[11] - Total operating costs decreased to CNY 957,440,753.08, down 26.4% from CNY 1,300,459,887.27 in the previous period[13] - Cash paid for employee compensation decreased slightly to CNY 159,473,556.56 from CNY 165,156,895.07 in the previous period[16] Inventory and Receivables - The company reported a 63.56% decrease in notes receivable at the end of the reporting period, attributed to increased payments of bank acceptance bills[5] - Inventory decreased by 35.09% compared to the beginning of the year, mainly due to a drop in the price of key raw materials[5] - Inventory decreased significantly from ¥602,010,484.51 to ¥390,770,971.42, a reduction of approximately 35.1%[10] - Accounts receivable rose to ¥270,788,117.63 from ¥225,031,849.78, indicating an increase of about 20.3%[10]